The Food and Drug Administration (FDA) has approved another Tdap vaccine option for use during pregnancy to prevent pertussis, otherwise known as whooping cough.
The FDA on January 9, 2022, licensed Adacel (Sanofi Pasteur) for immunization during the third trimester to prevent whooping cough in infants younger than 2 months old.
In October, the FDA approved a different Tdap vaccine known as Boostrix (GlaxoSmithKline) for the same indication. Boostrix was the first vaccine specifically approved to prevent a disease in newborns through vaccination during pregnancy.
These vaccines are groundbreaking because they offer protection for the neonates before the recommended age of the first dose of the vaccine at 2 months of age. “Tdap vaccination in pregnancy reduces the risk of pertussis infection by approximately 90% in a newborn’s first two months of life and reduces pertussis-related deaths by 95% in infants of vaccinated mothers.”1
The vaccine is now indicated for the following uses:
Active booster immunization against tetanus, diptheria and pertussis. Adacel is approved for use in people aged 10 to 64 years.
Immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age.
The vaccine is administered as a single, intramuscular injection shot.
According to the Centers for Disease Control and Prevention (CDC), pertussis starts as a common cold, but differs in that a patient can develop a cough that lasts for weeks or months. Being more severe in infants makes the Tdap vaccine that much more important for mothers.
Even healthy babies can get whooping cough, the CDC also wrote, because their immune systems are still developing. They may only have the antibodies they receive from their mother to help protect them from infections.
The CDC also said that many babies with whooping cough don’t cough at all. Instead, it wrote on its site, it may cause apnea and cause the baby to turn blue or struggle to breathe. It may also seem like the common cold for the duration of the illness, not only in the beginning.2
References
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Link between reproductive life span and postmenopausal muscle mass
November 30th 2023A recent study in Menopause, the journal of The Menopause Society, suggests that a longer reproductive life span and later age at menopause may be associated with a reduced risk of low handgrip strength in postmenopausal women.
Read More
How physicians can boost COVID-19 vaccine uptake among Spanish-speaking pregnant individuals
November 29th 2023Discover the crucial findings from a recent study investigating vaccine decision-making among Spanish-speaking pregnant individuals, highlighting the pivotal role doctors play in dispelling vaccine hesitancy and fostering acceptance through targeted information dissemination and culturally sensitive approaches.
Read More
NIDA study reports surge in pregnancy-associated drug overdose deaths
November 29th 2023Researchers from the National Institute on Drug Abuse unveil a 3-fold spike in drug overdose deaths among pregnant women aged 10 to 44 years between 2018 and 2021, highlighting pervasive barriers like discrimination and stigma hindering access to life-saving treatment.
Read More